Edition:
United States

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

3.75USD
22 Feb 2017
Change (% chg)

$0.05 (+1.35%)
Prev Close
$3.70
Open
$3.65
Day's High
$3.75
Day's Low
$3.65
Volume
3,135
Avg. Vol
27,454
52-wk High
$6.32
52-wk Low
$2.12

LIFE.OQ

Chart for LIFE.OQ

About

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based... (more)

Overall

Beta: --
Market Cap(Mil.): $86.57
Shares Outstanding(Mil.): 23.72
Dividend: --
Yield (%): --

Financials

  LIFE.OQ Industry Sector
P/E (TTM): -- 46.79 29.35
EPS (TTM): -2.61 -- --
ROI: -59.81 -3.72 12.97
ROE: -60.83 4.91 14.11

BRIEF-Ecor1 Capital reports 8.3 pct passive stake in Atyr Pharma

* Ecor1 Capital LLC reports 8.3 percent passive stake in Atyr Pharma Inc as of Jan 18 - SEC filing Source text: (http://bit.ly/2kkPDsu) Further company coverage:

Jan 30 2017

BRIEF-FDA grants fast track designation for aTyr's Resolaris

* Fda grants fast track designation for aTyr's Resolaris to treat limb girdle muscular dystrophy 2b and removes partial clinical hold for Resolaris

Jan 18 2017

BRIEF-Atyr Pharma enters into $20 million credit facility

* Intends to use additional capital to pay off existing indebtedness

Nov 21 2016

BRIEF-Atyr Pharma reports Q3 loss per share of $0.58

* Qtrly net loss per share attributable to common stockholders $0.58

Nov 14 2016

BRIEF-Atyr Pharma receives FDA fast track designation for Resolaris to treat FSHD

* Atyr Pharma receives FDA fast track designation for Resolaris to treat facioscapulohumeral muscular dystrophy (FSHD)

Oct 24 2016

More From Around the Web

Earnings vs. Estimates